Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia. John Ryan, Acting Director of the European Commission Public Health Directorate

1. Global Action on Dementia
Legacy Event
Session
"Barriers to investment in dementia
treatment research"
19 June 2014
John F. Ryan
Director Public Health
Health and Consumers Directorate General
European Commission

2. EU-level health policy actions
on dementia
Strategic Framework:
•Commission Communication “EU-initiative on Alzheimer’s disease
and other dementias” of 2009 (COM (2009) 380 final)
•Implementation report expected for July 2014
To be reported, i.a.:
•Joint Action ALCOVE (2011-2013) led by France;
•Context of EU-work on chronic disorders;
•European Innovation Partnership Active and Healthy Ageing;
•Conference "Health in Europe. Making it fairer", March 2014

3. (Million EUR)
EU Seventh Framework Programme for Research:
support to neurodegenerative diseases research
FP7

4. • - Understanding health, ageing and disease: determinants, risk
factors and pathways
• - New therapies for chronic non-communicable diseases
• - Comparing the effectiveness of existing healthcare interventions
in the elderly
• - ERA-NET: Establishing synergies between the Joint Programming
on Neurodegenerative Diseases Research and Horizon 2020
• - Development of new diagnostic tools and technologies: in vivo
medical imaging technologies
• - Tools and technologies for advanced therapies
Societal Challenge "Health, Demographic Change
and Wellbeing"
Call "Personalising health and care" (2014-2015)
Some topics relevant for dementia research
Horizon 2020
(2014-2020)

5. Courtesy of A. Maggi (JPND)
JPND

6. JPND
Achievements
 - € 68,5 million for transnational calls (2011-2014), 15 projects
ongoing (2011-2012; 2013-2014 call: projects selection on-going)
 - mapping national and European research and infrastructures
relevant to neurodegenerative diseases: searchable public database
Globalisation – third countries
 - Participation of Canada
 - Discussions with the USA started
 - Involved in the OECD follow-up activities of the G8 on dementia
EU support to JPND
 - FP7 Coordination Action Jumpahead (until August 2014)
 - H2020 – WP 2014: ERA-Net: Joint Programming - Establishing
synergies between the Joint Programming on Neurodegenerative
Diseases Research and Horizon 2020 (peer-review ongoing)

7. JPND
Achievements
 - € 68,5 million for transnational calls (2011-2014), 15 projects
ongoing (2011-2012; 2013-2014 call: projects selection on-going)
 - mapping national and European research and infrastructures
relevant to neurodegenerative diseases: searchable public database
Globalisation – third countries
 - Participation of Canada
 - Discussions with the USA started
 - Involved in the OECD follow-up activities of the G8 on dementia
EU support to JPND
 - FP7 Coordination Action Jumpahead (until August 2014)
 - H2020 – WP 2014: ERA-Net: Joint Programming - Establishing
synergies between the Joint Programming on Neurodegenerative
Diseases Research and Horizon 2020 (peer-review ongoing)